医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Company Profile for Mach7 Technologies Ltd.

2016年06月10日 PM11:40
このエントリーをはてなブックマークに追加


 

We believe that the patient is the center of healthcare delivery and that building, sharing and accessing a complete picture of the patient is critical to achieving optimal care outcomes. Mach7’s leading edge enterprise imaging solutions accelerate diagnosis and care delivery, reduce costs, and significantly improve patient outcomes.

Mach7 thinks about enterprise image management differently. We unlock and connect patient data scattered among silos of legacy healthcare systems allowing healthcare organizations to own, access and share patient data without boundaries. Mach7’s award-winning enterprise imaging platform provides a vendor neutral foundation for archiving, communication and consolidation of unstructured data. We power interoperability and enable healthcare enterprises to build their best-of-breed clinical ecosystems. With collaboration and partnership at the core of our customer relationships, Mach7’s solutions evolve to solve real-world workflow issues, simplify scalability challenges and ensure business continuity. Healthcare institutions around the world leverage Mach7 solutions for clinical productivity improvement, IT cost savings, health information exchange and regulatory compliance – all leading to improved patient care.

In 2016, Mach7 Technologies merged with 3D Medical, Australia’s leading medical specific 3D printing and holographic projection technology provider. 3D Medical’s solutions amplify human expertise by delivering accurate, patient-specific information in 3D to healthcare professionals. 3D Medical is a wholly owned subsidiary of Mach7 Technologies.

 

Company:

Mach7 Technologies Ltd.

 

Headquarters Address:

Level 1, Unit 4, 435 Williamstown Rd

 

Port Melbourne, VIC 3207

 

Australia

 

Main Telephone:

802-861-7745

 

Website:

www.mach7t.com

 

Ticker/ISIN:

M7T(ASX)/AU000000M7T0

 

Type of Organization:

Public

 

Industry:

Software

 

Earnings Release Dates:

1st Quarter: April 29, 2016

 

2nd Quarter: July 29, 2016

 

3rd Quarter: October 31, 2016

 

4th Quarter: January 31, 2017

 

Key Executives:

Managing Director and CEO: Albert Liong

 

Global CFO and CEO, Australia Operations: Jenni Pilcher

Public Relations

 

Contact:

Julia Vaughn

Phone:

802-768-0143

Email:

julia.vaughn@mach7t.com

 

Public Relations

 

Contact:

Sarah Lavoie

Phone:

802-448-4977

Email:

sarah.lavoie@mach7t.com

 

View source version on businesswire.com: http://www.businesswire.com/news/home/20160610005005/en/

CONTACT

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea
  • Minomic Announces Clinical Study Update for MILGa in Prostate, Bladder and Pancreatic Cancers
  • Tribogenics Signs HORIBA Scientific as Distribution Partner for Southeast Asia
  • ノボキュア・オプチューン(NovoTTF-100A)が 神経膠芽腫の治療用機器として厚生労働省より初発患者への適用拡大を承認
  • Completion of a Reserved Share Capital Increase of Median Technologies to FURUI of €19.6 Million at a €13 per Share Price